Hikma Pharmaceuticals’ (HIK) “Equal Weight” Rating Reiterated at Barclays

Barclays reiterated their equal weight rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research note published on Tuesday morning, MarketBeat.com reports. The firm currently has a GBX 2,000 ($25.13) target price on the stock.

Separately, Berenberg Bank reiterated a hold rating and issued a GBX 2,000 ($25.13) price objective on shares of Hikma Pharmaceuticals in a report on Thursday, April 25th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus price target of GBX 2,068.75 ($25.99).

Hikma Pharmaceuticals Stock Up 0.4 %

HIK stock opened at GBX 1,981 ($24.89) on Tuesday. The company has a current ratio of 1.57, a quick ratio of 1.27 and a debt-to-equity ratio of 53.92. The firm has a market capitalization of £4.40 billion, a PE ratio of 2,913.24, a PEG ratio of 2.38 and a beta of 0.44. Hikma Pharmaceuticals has a 1-year low of GBX 1,711 ($21.49) and a 1-year high of GBX 2,222 ($27.91). The business’s 50 day simple moving average is GBX 1,878.02 and its 200 day simple moving average is GBX 1,863.84.

Hikma Pharmaceuticals Increases Dividend

The company also recently declared a dividend, which was paid on Friday, May 3rd. Investors of record on Thursday, March 21st were paid a $0.47 dividend. The ex-dividend date of this dividend was Thursday, March 21st. This is an increase from Hikma Pharmaceuticals’s previous dividend of $0.25. This represents a yield of 1.86%. Hikma Pharmaceuticals’s payout ratio is 8,382.35%.

Insiders Place Their Bets

In other Hikma Pharmaceuticals news, insider Riad Mishlawi bought 736 shares of Hikma Pharmaceuticals stock in a transaction dated Tuesday, May 7th. The stock was bought at an average price of GBX 1,979 ($24.86) per share, with a total value of £14,565.44 ($18,298.29). Company insiders own 30.74% of the company’s stock.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.